

General information about company	
Scrip code*	543616
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE0MKA01014
Name of company	Trident Lifeline Limited
Type of company	SME
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	11-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	04-11-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Half Yearly
Reporting Quarter	Half yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	11-11-2025 19:00
End date and time of board meeting	11-11-2025 19:50
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	No
Latest Date on which RPT policy is updated	
Indicate Company website link for updated RPT policy of the Company	
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
	NA

Financial Results – Other than Bank			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Revenue From Operations		
	Revenue from operations	4625.86	4625.86
	Other income	164.32	164.32
	Total Income	4790.18	4790.18
2	Expenses		
(a)	Cost of materials consumed	2760.27	2760.27
(b)	Purchases of stock-in-trade	114.25	114.25
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-244.77	-244.77
(d)	Employee benefit expense	180.39	180.39
(e)	Finance costs	74.36	74.36
(f)	Depreciation and amortisation expense	110.55	110.55
(g)	Other Expenses		
1	Other Expenses	684.67	684.67
	Total other expenses	684.67	684.67
	Total expenses	3679.72	3679.72
3	Profit before exceptional and extraordinary items and tax	1110.46	1110.46
4	Exceptional items	0	0
5	Profit before extraordinary items and tax	1110.46	1110.46
6	Extraordinary items	0	0
7	Profit before tax	1110.46	1110.46
8	Tax Expense		
	Current tax	268.75	268.75
	Deferred tax	0	0
	Total tax expenses	268.75	268.75
9	Net Profit Loss for the period from continuing operations	841.71	841.71
10	Profit (loss) from discontinuing operations before tax	0	0
11	Tax expense of discontinuing operations	0	0
12	Net profit (loss) from discontinuing operation after tax	0	0
13	Profit (loss) for period before minority interest	841.71	841.71
14	Share of profit (loss) of associates		
15	Profit (loss) of minority interest		
16	Net profit (Loss) for the period	841.71	841.71
17	Details of equity share capital		
	Paid-up equity share capital	1159.22	1159.22
	Face value of equity share capital	10	10
	Details of debt securities		
18	Reserves excluding revaluation reserve		
19	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	7.26	7.26
	Diluted earnings (loss) per share from continuing and discontinued operations	7.26	7.26
20	Debt equity ratio		
			Textual Information(1)

21	Debt service coverage ratio			Textual Information(2)
22	Interest service coverage ratio			Textual Information(3)
23	Disclosure of notes on financial results			

Statement of Asset and Liabilities		
	Particulars	Half Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	30-09-2025
	Whether results are audited or unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone
	Equity and liabilities	
1	Shareholders' funds	
	Share capital	1159.22
	Reserves and surplus	6502.51
	Money received against share warrants	
	Total shareholders' funds	7661.73
2	Share application money pending allotment	599.3
3	Deferred government grants	
4	Minority interest	
5	Non-current liabilities	
	Long-term borrowings	606.81
	Deferred tax liabilities (net)	45.78
	Foreign currency monetary item translation difference liability account	
	Other long-term liabilities	7.02
	Long-term provisions	0
	Total non-current liabilities	659.61
6	Current liabilities	
	Short-term borrowings	1465.14
	Trade Payables	
	(A) Total outstanding dues of micro enterprises and small enterprises	742.13
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	1041.8
	Total Trade payable	1783.93
	Other current liabilities	366.06
	Short-term provisions	382.47
	Total current liabilities	3997.6
	Total equity and liabilities	12918.24
	Assets	
1	Non-current assets	
(i)	Property, Plant and Equipment and Intangible assets	
	Property, Plant and Equipment	903.31
	Producing properties	
	Intangible assets	844.68
	Preproducing properties	
	Property, Plant and Equipment capital work-in-progress	53.72
	Intangible assets under development or work-in-progress	
	Total Property, Plant and Equipment and Intangible assets	1801.71
(ii)	Non-current investments	1463.73
(v)	Deferred tax assets (net)	
(vi)	Foreign currency monetary item translation difference asset account	
(vii)	Long-term loans and advances	81.66
(viii)	Other non-current assets	1.2
	Total non-current assets	3348.3
2	Current assets	
	Current investments	0
	Inventories	1897.33
	Trade receivables	3493.5
	Cash and cash equivalents	230.63
	Bank balance other than cash and cash equivalents	0

	Short-term loans and advances	3191.57
	Other current assets	756.91
	Total current assets	9569.94
	Total assets	12918.24

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results		
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025	01-04-2025
Date of end of reporting period	30-09-2025	30-09-2025
Whether results are audited or unaudited	Unaudited	Unaudited
Nature of report standalone or consolidated	Standalone	Standalone
1 Segment Revenue		
(net sale/income from each segment should be disclosed)		
Total segment revenue		
Less: Inter segment revenue		
Revenue from operations		
2 Segment Result		
Profit (+) / Loss (-) before tax and interest from each segment		
Total Profit before tax		
i. Finance cost		
ii. Other unallocable expenditure net off unallocable income		
Profit before tax		
3 (Segment Asset - Segment Liabilities)		
Segment Asset		
Total Segment Assets		
Un-allocable Assets		
Net Segment Assets		
4 Segment Liabilities		
Segment Liabilities		
Total Segment Liabilities		
Un-allocable Liabilities		
Net Segment Liabilities		

Cash flow statement - indirect	
Particulars	Half Year ended (dd-mm-yyyy)
Date of start of reporting period	01-04-2025
Date of end of reporting period	30-09-2025
Whether results are audited or unaudited	Unaudited
Nature of report standalone or consolidated	Standalone
1 Statement of cash flows	
Cash flows from used in operating activities	
Profit before extraordinary items and tax	1110.46
2 Adjustments for reconcile profit (loss)	
Adjustments to profit (loss)	
Adjustments for finance costs	74.36
Adjustments for depreciation and amortisation expense	110.55
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
Adjustments for unrealised foreign exchange losses gains	0
Adjustments for dividend income	0
Adjustments for share-based payments	0
Other adjustments for which cash effects are investing or financing cash flow	0
Other adjustments to reconcile profit (loss)	0
Other adjustments for non-cash items	0
Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
Total adjustments to profit (loss)	184.91
3 Adjustments for working capital	
Adjustments for decrease (increase) in inventories	-240.1
Adjustments for decrease (increase) in trade receivables	-1453.34
Adjustments for decrease (increase) in other current assets	-278.58
Adjustments for increase (decrease) in trade payables	818.96
Adjustments for increase (decrease) in other current liabilities	-68.75
Adjustments for provisions	-546.43
Total adjustments for working capital	-1768.24
Total adjustments for reconcile profit (loss)	-1583.33
Net cash flows from (used in) operations	-472.87
Dividends received	0
Interest paid	0
Interest received	0
Income taxes paid (refund)	268.75
Other inflows (outflows) of cash	-82.57
Net cash flows from (used in) operating activities before extraordinary items	-824.19
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) operating activities	-824.19
4 Cash flows from used in investing activities	
Cash flows from losing control of subsidiaries or other businesses	0
Cash flows used in obtaining control of subsidiaries or other businesses	0
Other cash receipts from sales of equity or debt instruments of other entities	0
Other cash payments to acquire equity or debt instruments of other entities	0
Other cash receipts from sales of interests in joint ventures	0
Other cash payments to acquire interests in joint ventures	0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
Proceeds from sales of property plant and equipment	0
Purchase of property plant and equipment	0
Proceeds from sales of intangible assets	0
Purchase of intangible assets	0

Cash advances and loans made to other parties	0
Cash receipts from repayment of advances and loans made to other parties	0
Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
Dividends received	0
Interest received	82.97
Income taxes paid (refund)	0
Other inflows (outflows) of cash	-593.94
Proceeds from government grants	0
Net cash flows from (used in) investing activities before extraordinary items	-510.97
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) investing activities	-510.97
5 Cash flows from used in financing activities	
Proceeds from issuing shares	9.3
Proceeds from issuing other equity instruments	0
Proceeds from issuing debentures notes bonds etc	0
Proceeds from borrowings	615.6
Repayments of borrowings	0
Dividends paid	0
Interest paid	0
Income taxes paid (refund)	0
Other inflows (outflows) of cash	729.85
Net cash flows from (used in) financing activities before extraordinary items	1354.75
Proceeds from extraordinary items	0
Payment for extraordinary items	0
Net cash flows from (used in) financing activities	1354.75
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	19.59
6 Effect of exchange rate changes on cash and cash equivalents	
Effect of exchange rate changes on cash and cash equivalents	0
Net increase (decrease) in cash and cash equivalents	19.59
Cash and cash equivalents cash flow statement at beginning of period	211.02
Cash and cash equivalents cash flow statement at end of period	230.61

Format for Disclosure of Related Party Transactions (applicable only for half

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary							
1	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Sale of goods or services			as approved by Board and members			103.9%
2	TRIDENT LIFELINE LIMITED	AAECT8906D	TALON HEALTHCARE LLP	AAMFT9597P	DIRECTOR'S INTEREST	Sale of goods or services			as approved by Board and members			185.30
3	TRIDENT LIFELINE LIMITED	AAECT8906D	TENCH LIFE SCIENCES LLP	AAMFT9299A	DIRECTOR'S INTEREST	Sale of goods or services			as approved by Board and members			192.54
4	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Purchase of goods or services			as approved by Board and members			281.9%
5	TRIDENT LIFELINE LIMITED	AAECT8906D	TRIDENT MEDIQUIP LIMITED	AAHCT5650R	SUBSIDIARY COMPANY	Interest received			as approved by Board and members			11.29
6	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Interest received			as approved by Board and members			17.45
7	TRIDENT LIFELINE LIMITED	AAECT8906D	TRIDENT MEDIQUIP LIMITED	AAHCT5650R	SUBSIDIARY COMPANY	Loan			as approved by Board and members			624
8	TRIDENT LIFELINE LIMITED	AAECT8906D	TNS PHARMA PRIVATE LIMITED	AAJCT0904G	SUBSIDIARY COMPANY	Loan			as approved by Board and members			193.7%
9	TRIDENT LIFELINE LIMITED	AAECT8906D	TALON HEALTHCARE LLP	AAMFT9597P	DIRECTOR'S INTEREST	Loan			as approved by Board and members			50.2
10	TRIDENT LIFELINE LIMITED	AAECT8906D	TENCH LIFE SCIENCES LLP	AAMFT9299A	DIRECTOR'S INTEREST	Loan			as approved by Board and members			174.1%
11	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL ELEMENTS PRIVATE LIMITED	AAKCT9256C	SUBSIDIARY COMPANY	Loan			as approved by Board and members			0
12	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL HERBAL LIMITED	AAHCT6372N	SUBSIDIARY COMPANY	Loan			as approved by Board and members			107
13	TRIDENT LIFELINE LIMITED	AAECT8906D	TLL PARENTERALS LIMITED	AAKCT6315Q	SUBSIDIARY COMPANY	Loan			as approved by Board			171.9

									and members			
14	TRIDENT LIFELINE LIMITED	AAECT8906D	TRICORP INDUSTRIES LIMITED	AAKCT0602Q	DIRECTOR'S INTEREST	Loan			as approved by Board and members			6.9
15	TRIDENT LIFELINE LIMITED	AAECT8906D	VN CAPITAL SERVICES LLP	AAOFV5800F	DIRECTOR'S INTEREST	Loan			as approved by Board and members			150
Total value of transaction during the reporting period												2270.3

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Public Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	04-10-2022
Amount Raised	3534.19
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	NA
Comments of the auditors, if any	NA

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	To meet working capital requirements	NA	2050	0	2029.65	0	
2	Product registration in the international markets	NA	513.66	0	61.74	0	
3	General Corporate Purpose	NA	670.53	0	670.48	0	
4	Public issue expense	NA	300	0	300	0	

Signatory Details	
Name of signatory	NIKITA SHARMA
Designation of person	Company Secretary and Compliance Officer
Place	SURAT
Date	11-11-2025

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	09-06-2025
Amount Raised	2657.34
Report filed for Quarter ended	30-09-2025
Monitoring Agency	Not applicable
Monitoring Agency Name, if applicable	
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	NA
Comments of the auditors, if any	NA

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	to Meet Working Capital requirements, to make investments in subsidiaries/associates/joint ventures and to meet their working capital requirements, repayment of Secured borrowings of the Company, Business Expansion and other general corporate purposes	NA	2657.34	0	846.67	0	

